On December 3, 2024, Lazarus Krikorian, Senior Vice President & Chief Accounting Officer at Cencora Inc, executed a sale of 1,816 shares of the company. Following this transaction, the insider now holds 21,988 shares of Cencora Inc.
Cencora Inc (COR, Financial) is a leading global healthcare solutions company that provides pharmaceutical distribution and related services designed to improve patient outcomes. The company operates in various segments, including pharmaceutical distribution, specialty solutions, and consulting services, catering to healthcare providers, manufacturers, and patients.
The insider transaction history for Cencora Inc indicates a trend of more insider selling than buying over the past year. Specifically, there has been one insider purchase and 24 insider sales during this period.
On the day of the transaction, shares of Cencora Inc were trading at $250.42, giving the company a market cap of $47,999.191 million. The company's price-earnings ratio stands at 33.07, which is higher than the industry median of 19.6 and also above the company's historical median price-earnings ratio.
The GF Value for Cencora Inc is estimated at $220.85, resulting in a price-to-GF-Value ratio of 1.13. This suggests that the stock is modestly overvalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples, a GuruFocus adjustment factor, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
